^
Association details:
| Biomarker: | Chr del(17p) |
|---|---|
| Cancer: | Chronic Lymphocytic Leukemia |
| Drug: | Zydelig (idelalisib) (PI3Kδ inhibitor) + Arzerra (ofatumumab) (CD20 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Published date:
09/18/2014
Excerpt:
Zydelig is indicated in combination with an anti‑CD20 monoclonal antibody (rituximab or ofatumumab) for the treatment of adult patients with chronic lymphocytic leukaemia (CLL):...as first line treatment in the presence of 17p deletion or TP53 mutation in patients who are not eligible for any other therapies...
